{
  "id": 19561311,
  "title": "Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?",
  "url": "https://urgent.news/2026/11/11/eli-lilly-just-raised-its-2026-sales-forecast-to-as-much-as-92",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-11T22:34:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/11/eli-lilly-just-raised-its-2026-sales-forecast-to-a/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly (LLY) has raised its 2026 sales forecast to as much as $92 billion, driven by its leadership in the weight loss market. The company's revenue grew by 39% year-over-year to $24.4 billion in the third quarter, with Zepbound sales increasing by 49% to $5.4 billion. This success has led to an increase in Eli Lilly's sales guidance from $85 billion to $87 billion to between $91 billion and $92 billion. However, Viking Therapeutics (VKTX), a clinical-stage biotech, may pose a challenge to Eli Lilly's dominance in the weight-loss market. Viking's leading candidate, VK2735, mimics the actions of the gut hormones GLP-1 and GIP, similar to Zepbound. Preliminary clinical trial results for VK2735 have been promising, with mean weight loss of up to 14.7% in a Phase 2 study. If this success continues, Viking Therapeutics could become a major player in the weight-loss market. However, competition from other companies, including Eli Lilly, could put pressure on Viking's stock price.",
  "summary": "These drugmakers offer very different risk-reward profiles.",
  "key_points": [
    "Eli Lilly raises 2026 sales forecast to $92 billion, citing weight loss market leadership.",
    "Zepbound sales increase 49% to $5.4 billion in Q3, contributing to revenue growth.",
    "Viking Therapeutics' VK2735 shows promising 14.7% weight loss in Phase 2 trial."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?",
        "url": "https://urgent.news/2026/11/11/eli-lilly-just-raised-its-2026-sales-forecast-to-as-much-as-92-19570634",
        "published": "2026-11-11T22:54:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}